Cargando…
Fetal hemoglobin level and nutritional status in patients with sickle cell disease
Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is importa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939000/ https://www.ncbi.nlm.nih.gov/pubmed/27390841 http://dx.doi.org/10.1186/s12937-016-0181-x |
_version_ | 1782441943027941376 |
---|---|
author | Badawy, Sherif M. |
author_facet | Badawy, Sherif M. |
author_sort | Badawy, Sherif M. |
collection | PubMed |
description | Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients’ nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age. |
format | Online Article Text |
id | pubmed-4939000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49390002016-07-10 Fetal hemoglobin level and nutritional status in patients with sickle cell disease Badawy, Sherif M. Nutr J Letter to the Editor Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients’ nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age. BioMed Central 2016-07-08 /pmc/articles/PMC4939000/ /pubmed/27390841 http://dx.doi.org/10.1186/s12937-016-0181-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Letter to the Editor Badawy, Sherif M. Fetal hemoglobin level and nutritional status in patients with sickle cell disease |
title | Fetal hemoglobin level and nutritional status in patients with sickle cell disease |
title_full | Fetal hemoglobin level and nutritional status in patients with sickle cell disease |
title_fullStr | Fetal hemoglobin level and nutritional status in patients with sickle cell disease |
title_full_unstemmed | Fetal hemoglobin level and nutritional status in patients with sickle cell disease |
title_short | Fetal hemoglobin level and nutritional status in patients with sickle cell disease |
title_sort | fetal hemoglobin level and nutritional status in patients with sickle cell disease |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939000/ https://www.ncbi.nlm.nih.gov/pubmed/27390841 http://dx.doi.org/10.1186/s12937-016-0181-x |
work_keys_str_mv | AT badawysherifm fetalhemoglobinlevelandnutritionalstatusinpatientswithsicklecelldisease |